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Abstract
In November 2001, drotrecogin alfa (activated) was approved by
the US Food and Drug Administration; in August 2002 it was
approved by the European Medicines Agency. Since the approval
of drotrecogin alfa (activated), however, critical care physicians
have been faced with several challenges, namely its costs,
selection of patients who are more likely to benefit from it, and the
decision regarding when to start drotrecogin alfa (activated)
treatment. There are also operational issues such as how to
manage the infusion to deliver an effective treatment while
minimizing the risk for bleeding, particularly in patients with
deranged clotting, at around the time of surgery or during renal
replacement therapy. While addressing these issues, this review
remains practical but evidence based as much as possible.
Introduction
Severe sepsis and septic shock respectively account for
about 37% and 15% of patients admitted to intensive care
units (ICUs) in Europe [1]. They are also the leading causes
of death [2], with 27% and 47% ICU mortality, and 36% and
57% hospital mortality, respectively [1]. Data from the
Intensive Care National Audit and Research Centre in
England, Wales, and Northern Ireland show that the number
of patients with severe sepsis admitted to the ICU is
increasing over time [3], which is responsible for an increase
in the absolute number of deaths, despite an improved
standard of care and reduced hospital mortality.
The mechanisms that lead to organ dysfunction in severe
sepsis are complex. Deranged procoagulant and proinflam-
matory host responses to infection can lead to endothelial
damage, impairment of the microcirculation and tissue
hypoperfusion [4,5]. In this intricate system, activated protein
C plays a key role in preserving and restoring tissue perfusion
through its potent antithrombotic, profibrinolytic, and anti-
inflammatory properties [6-8].
During systemic sepsis, however, inflammation and endo-
thelial dysfunction impair the conversion of protein C (PC) to
its activated protein C form. Hence, almost 88% of patients
with sepsis have low levels of PC (<80% of normal), and
40% have levels of PC that are severely reduced (<40% of
normal) [9]. This can lead to excessive inflammation, forma-
tion of microthrombi and multiple organ failure, with an
associated poor outcome [6,7,10,11].
Drug approval and guidelines
In 2001 the Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) trial
was reported [9]. It found that a 96-hour intravenous infusion
(24 μg/kg per hour) of drotrecogin alfa (activated; DrotAA), a
recombinant human activated protein C (Xigris®; Eli Lilly and
Company, Indianapolis, IN, USA), caused a relative risk
reduction (RRR) for mortality at 28 days of 19.4% (95%
confidence interval [CI] 6.6% to 30.5%). The absolute risk
reduction (ARR) for mortality was 6.1% (95% CI 1.9% to
10.4%) and the number needed to treat (NNT) to save one
additional life was 16 (95% CI 52.6 to 9.6) [9]. In November
2001 DrotAA was approved by the US Food and Drug
Administration (FDA); in August 2002 it was approved by the
European Medicines Agency (EMEA). Both organizations
licensed DrotAA for use in patients with severe sepsis at high
risk for death, but they differed in their definition of risk for
death. High risk for death was defined by the US label as an
Acute Physiology and Chronic Health Evaluation (APACHE) II
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score of 25 or more (as indicated by subgroup data from
PROWESS) and by the European Union label as the
presence of multiple organ dysfunction. The European Union
decision was based on the greater survival benefit observed
in patients with two or more organ dysfunctions who were
treated with DrotAA (RRR 22% and ARR 7.4%; NNT 13.5),
with a bleeding risk similar to that in the overall study
population [12,13].
The use of DrotAA has also been endorsed by international
societies and included in the Surviving Sepsis Campaign
(SSC) guidelines. In the UK, DrotAA is recommended by the
National Institute for Clinical Excellence for use in adults with
multiple organ failure secondary to severe sepsis who are
provided with optimum intensive care support [14].
A condition of the initial approval of DrotAA by the FDA in
2001 was that additional data were to be provided and
further trials conducted. Specifically, data from the long-term
follow up of survivors from the PROWESS study were to be
submitted [15]. Safety and efficacy of DrotAA were to be
evaluated in adult patients at lower risk for death (the
Administration of Drotrecogin Alfa [Activated] in Early Stage
Severe Sepsis [ADDRESS] trial [16]). Safety and efficacy of
DrotAA in paediatric patients with severe sepsis were to be
evaluated (the REsearching severe Sepsis and Organ
dysfunction in children: a gLobal perspectiVE [RESOLVE]
trial [17]). Finally, a study was to be conducted to determine
whether low-dose heparin has an effect on mortality in adult
patients who are receiving DrotAA (the Xigris and
Prophylactic HepaRin Evaluation in Severe Sepsis [XPRESS]
trial [18]).
In February 2007, following discussions with the EMEA and
because of ongoing equipoise among some critical care
physicians, Lilly announced that they would be conducting a
further trial of DrotAA in the currently indicated population.
This new trial (known as PROWESS Shock) is planned to
start in 2008.
Since the approval of DrotAA, however, critical care
physicians have been faced with several challenges: its
costs, the selection of patients who are more likely to benefit
from it, and the decision on when to start DrotAA. There are
also operational issues on how to manage the infusion in
order to deliver an effective treatment while minimizing the
risk for bleeding, particularly in patients with deranged
clotting, at around the time of surgery or during renal replace-
ment therapy.
Use of drotrecogin alfa (activated) in adults
Does drotrecogin alfa (activated) increase survival in
severe sepsis?
The PROWESS trial and subsequent registries in different
nations have documented a consistent reduction in mortality
in patients with severe sepsis when treated with DrotAA
(Table 1). Following publication of the PROWESS trial
findings [9], the open-label Extended Evaluation of Recom-
binant Human Activated Protein C (ENHANCE) trial [19]
showed a mortality rate similar to that in PROWESS, adding
further support to the findings of the original controlled trial.
Descriptive analyses of national registries have also
confirmed that the results of the PROWESS trial are robust.
According to the findings of the global Promoting Global
Research Excellence in Severe Sepsis database of 12,492
patients with severe sepsis from 37 countries [20], the
adjusted odds ratio (OR) for hospital mortality associated
with DrotAA was 0.75 (95% CI 0.63 to 0.90; P = 0.002),
which is similar to that observed in the PROWESS trial (OR
0.8, 95% CI 0.69 to 0.94) [9]. Similarly, in the UK, Intensive
Care National Audit and Research Centre data indicate that
the relative risk for death associated with DrotAA was
between 0.75 (95% CI 0.68 to 0.83) and 0.85 (95% CI 0.78
to 0.93) [21]. These studies also demonstrate a greater
treatment effect for patients with three or more organs in
failure, with an ARR for dying of up to 17% [20,21].
These data are consistent with the clinical experiences of
other national registries. Data from a Polish registry showed
that patients treated with DrotAA with a mean of 3.7 organs
in failure had an ARR for death of 17.3% (38.9% versus
56.2%), giving an NNT of 6 [22]. In the group of patients with
APACHE II scores of 25 or more, the absolute mortality risk
was reduced by 13% [22]. Likewise, a Belgian registry
suggested that DrotAA reduced the odds of death by 39%
(OR 0.61, 95% CI 0.40 to 0.92), with an adjusted ARR of
12.8% (expected versus observed mortality of 63.5% versus
50.7%) [23,24]. Data from an Italian pharmaco-surveillance
registry showed an 8.4% ARR in patients treated with
DrotAA (46.4% versus 54.9%; P = 0.0004), but these data
must be interpreted with caution because the untreated
group included older patients and a greater percentage of
patients in septic shock (66.8% versus 77.1%; P < 0.0001)
who were therefore at greater risk for death [25].
Also favourable are the long-term outcome data. Follow-up
data from the PROWESS study showed that hospital survival
is greater with DrotAA (70.3% versus 65.1% for placebo)
[15], with no extra ICU resource use apart from the DrotAA
acquisition cost [26]. Patients with more severe disease and
an APACHE II score of 25 or more had a longer median
survival time (379 days), and an additional 11% of patients in
the DrotAA group were alive at 1 year [15].
Which patients should be considered for treatment with
drotrecogin alfa (activated)?
Faced with the decision of whom to treat with DrotAA,
intensivists should consider in which patients is treatment
with DrotAA indicated, and in which patients is the greatest
benefit in terms of both mortality and cost-effectiveness likely
to be realized.Page 3 of 8
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Most of the trials have used inclusion and exclusion criteria
similar to those in the PROWESS trial [9]. In our experience,
in which we have treated more than 300 patients with
DrotAA, the exclusion criteria most frequently encountered
are severe chronic illness, high bleeding risk, advanced
cancer, excluded concomitant medication, expected survival
under 24 hours, and severe thrombocytopenia (platelet count
<30,000/mm3) [27].
It is clear that the key to appropriate use of DrotAA lies in the
assessment of risk for death. However, there is still no
consensus on a good operational definition of ‘high risk’ in
patients with severe sepsis. In the USA DrotAA is recom-
mended in patients ‘at high risk of death, for example, those
with an APACHE II score of =25’, whereas in the European
Union DrotAA is indicated in the presence of multiple organ
dysfunction, irrespective of pretreatment APACHE II score.
The recommendations of the SSC guidelines are based on
APACHE II score, organ dysfunction, the presence of septic
shock and sepsis-induced acute respiratory distress syn-
drome, but the SSC also acknowledges the lack of a clear
definition of high risk and emphasizes the importance of
clinical judgement in guiding timely treatment with DrotAA [4].
Using the APACHE II score to select patients for treatment
with DrotAA has several limitations. Initially, this score was
developed for use in populations, not to inform decisions in
individual patients. Moreover, the APACHE II score in the
PROWESS trial was calculated based on data obtained
within the 24 hours before study randomization, not during
the first 24 hours in the ICU. This renders the APACHE score
problematic in assisting patient selection because physio-
logical parameters change continuously and are modified by
treatment. The APACHE II score may change but not
necessarily the severity of the underlying process [7]. In spite
of this, an APACHE score above 25 did appear to identify a
group of patients who were highly likely to experience a long-
term survival benefit [15].
Results from the ADDRESS trial [16], which was conducted
in patients at ‘lower risk of death’, confirmed that the original
decisions of the FDA and EMEA may have been correct in
terms of the wording of their licences. In this trial, enrolment
was terminated early because interim analysis revealed a low
likelihood that DrotAA would significantly reduce the 28-day
mortality rate. Of the 2,613 patients, including 1,297 in the
placebo group and 1,316 in the DrotAA group, both groups
had similar 28-day mortality (17.0% with placebo versus
18.5% with DrotAA; P = 0.34) and in-hospital mortality
(20.5% versus 20.6%; P = 0.98).
Static or dynamic assessment of risk for death
In patients with severe sepsis, the number of organs in failure
is frequently used for prognostication at the bedside. In
addition, multiple scoring systems (for instance, the
Sequential Organ Failure Assessment [SOFA] score and the
Multiple Organ Dysfunction Score) were developed to help
clinicians to summarize organ dysfunction and to predict risk
for death [28,29]. Although the degree of organ dysfunction
at baseline, calculated for example using a SOFA score, is
highly predictive of 28-day mortality, it appears probable that
a single assessment in time is inferior to assessment of
dynamic changes (for instance, delta SOFA) [30,31]. Using
such a dynamic measurement over time more closely reflects
the patient’s response to therapeutic interventions [32], in
that improvement in cardiovascular, renal, or respiratory
function from baseline to day 1 is significantly related to
improved survival. For example, based on static baseline
measurements, the mortality rate in patients not receiving
vasopressors decreased by 6% if they remained on no
vasopressors; it increased by 11% and 32% if patients
required a low or high dose of vasopressors, respectively, at
day 1 [32]. The effects of DrotAA on dynamic changes in
vasopressor use and SOFA score during the first 24 hours
of treatment with DrotAA are currently being tested in a
phase IV open label trial, which is expected to complete
recruitment in December 2007 (http://clinicaltrials.gov/ct2/
show/NCT00279214?term=drotrecogin&rank=4).
As well as using baseline organ dysfunction to predict
mortality, dynamic assessment of the plasma level of PC
concentration has been shown to predict mortality in
Available online http://ccforum.com/content/11/S5/S7
Table 1
Effects of drotrecogin on mortality in National Registry data
Registry/Trial Country Patients treated with DrotAA (% of cases) ARR OR (95% CI)
PROWESS International 1,690 6.1% 0.8 (0.69 to 0.94)
UK [21]  1,245 (6.3%) 0.75 (0.68 to 0.83)
Poland [22]  302 (9.3%) 17.3%
PROGRESS International [20]  882 (7%) 0.75 (0.63 to 0.9)
Belgium [24] 430 12.8% 0.61 (0.40 to 0.92)
ARR, absolute risk reduction; CI, confidence interval; DrotAA, drotrecogin alfa (activated); OR, odds ratio; PROGRESS, Promoting Global
Research Excellence in Severe Sepsis; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.severe sepsis [33]. In particular, having low PC levels
(<40% of normal) carries an OR for death of 2.75. The OR
ratio improved to 0.43 if levels rose above 40% of normal
on day 1. Conversely, for patients with PC above 40%, a
decrease by more than 10% increased the risk for death by
1.78 [33]. Perhaps these changes could be used not only
prognostically but also to guide treatment in terms of the
dose and duration of DrotAA therapy. A phase II clinical
trial (RESPOND trial [Research Evaluating Serial Protein C
levels in severe sepsis patients ON Drotrecogin alfa
(activated)]; NCT00386425; http://clinicaltrials.gov/ct2/
show/NCT00386425?term=drotrecogin&rank=6) is eval-
uating the impact of different doses and duration of treatment
with DrotAA on the change of plasma levels of PC using
serial measurements of PC in patients with severe sepsis.
Effects of drotrecogin alfa (activated) in different
clinical subgroups
Demographics
Several subgroup analyses of the PROWESS trial have been
performed based on clinical and biochemically relevant
baseline variables. These analyses have found that the
relative risk reductions in these subgroups were not
statistically different from those in the overall population and
allow substantial confidence that the overall study result was
robust. In particular, the subgroup analysis of elderly patients
(>75 years) who were treated with DrotAA demonstrated
ARRs in 28-day mortality of 15.5%, with a relative risk of 0.68
(95% CI 0.54 to 0.87) and a NNT of 6 to 7, and similar rates
of serious adverse events [34].
Community-acquired pneumonia
A subgroup analysis was conducted in patients with severe
sepsis caused by community-acquired pneumonia (CAP),
with a CURB-65 (confusion, urea, respiratory rate, blood
pressure, age >65 years) score of above 3, who were treated
with DrotAA [35]. It demonstrated a RRR in mortality of 28%
at 28 days, and of 14% at 90 days. The survival benefit was
most pronounced in severe CAP patients with Streptococcus
pneumoniae infection and in CAP patients at high risk for
death, as indicated by an APACHE II score above 25,
Pneumonia Severity Index score above 4, or CURB-65 score
above 3.
Purpura fulminans meningitis and meningococcal disease
A small proportion (4.6%) of patients from the PROWESS
and ENHANCE trials and a compassionate use programme
(study EVAS) had purpura fulminans, meningitis, or meningo-
coccal disease. Overall, these patients exhibited an ARR of
6.5%, similar to that in the PROWESS study. When analyzed
in isolation, however, the ARRs of death after DrotAA were
16.7% for meningococcal disease, 7.1% for meningitis, and
4% for purpura fulminans [36]. The rate of severe bleeding
events was similar to that in the rest of the population, but
there was a higher rate of intracranial haemorrhage (4.3%
versus 1%), with the highest rate being recorded for
meningitis (5.7%). This may simply reflect the high risk for
developing intracranial haemorrhage in this population,
independent of DrotAA. It is noteworthy that despite the
higher total number of bleeding events, the number of fatal
bleeding events was similar to that in the rest of the
population, both during the infusion period (0.6% versus
0.4%) and over the 28-day period (0.6% versus 0.8%) [36].
Surgical patients
Of patients included in the PROWESS population, 28% had
undergone surgery within the 30-day period prior to study
entry. Overall, these patients exhibited a smaller mortality
benefit of 3.2%; however, the subpopulation of patients who
underwent an abdominal operation had an overall 9.1% ARR
and 30% RRR (relative risk 0.7, 95% CI 0.48 to 1.03). When
patients with an APACHE II score of 25 or greater were
considered, the ARR was even higher, at 18.2%, and the
RRR was 40% (relative risk 0.6, 95% CI 0.36 to 1.0) [37].
The rates of serious bleeding events were not dissimilar from
those in nonsurgical patients (3.1% versus 2.1% during the
infusion period, and 3.5% versus 3.5% during the 28-day
period) [37]. Furthermore, data from INDEPTH (International
Integrated Database for the Evaluation of Severe Sepsis and
DrotAA Therapy) [38] showed a significant reduction in
mortality (OR 0.66, 95% CI 0.45 to 0.97) in surgical patients
with severe sepsis and a high risk for death. Surgical patients
at a lower risk for death do not appear to benefit from therapy
with DrotAA.
Pancreatitis
Acute severe pancreatitis leads to a marked systemic inflam-
matory response; however, the role played by infection during
the acute phase of the disease is unclear. Patients with
pancreatitis admitted to the ICU have mortality rates in the
range of 30% to 50% and a mean hospital length of stay in
excess of 1 month [39]. One of the complications is the
occurrence of a catastrophic retroperitoneal haemorrhage.
For this reason, patients with acute pancreatitis but without
evidence of infection were excluded from the PROWESS
trial. However, 62 patients (3.7% of the patients) with
pancreatitis and severe sepsis were enrolled in the trial. In
these patients, mortality was 24% in the placebo arm and
15% in those receiving DrotAA (ARR 9% and NNT 11).
Experience outside clinical trials also supports careful use of
DrotAA in the context of infection and pancreatitis [40]. The
International Consensus Conference on severe acute pancrea-
titis recommended that use of DrotAA be considered together
with conventional treatment in patients with severe acute
pancreatitis and severe sepsis, bearing in mind the theoretical
but unproven concern of retroperitoneal haemorrhage [39,41].
Disseminated intravascular coagulation
Although a baseline thrombocytopenia (platelet count
<30,000/mm3) was an exclusion criterion in the PROWESS
Critical Care    Vol 11 Suppl 5 Camporota and Wyncoll
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strated an increased survival benefit in patients with overt
disseminated intravascular coagulation (DIC) treated with
DrotAA as compared with patients without DIC or those
treated with placebo [5,42], with similar serious bleeding
event rates. The benefits of DrotAA in patients with DIC has
also been confirmed in the recent RESOLVE trial [17], in
which there was a 7.8% ARR in 28-day mortality in patients
with DIC treated with DrotAA.
Thrombocytopenia
Patients with a platelet count below 30,000/mm3 are at
greater risk for bleeding, particularly intracranial haemorrhage,
associated with use of DrotAA. Of deaths due to bleeding in
the PROWESS trial, 66% occurred during the infusion. Of
these, 75% occurred in patients with severe thrombocyto-
penia (platelet count <30,000/mm3). The FDA and the EMEA
differ in that they consider severe thrombocytopenia relative
and absolute contraindications to the use of DrotAA,
respectively. Consequently, it is advisable that patients with a
baseline platelet count below 30,000/mm3 be treated by
those experienced in the use of DrotAA after careful
evaluation of the risks and benefits for the individual patient.
However, if during the infusion there is a decrease in platelet
count to below 30,000/mm3, platelet transfusion should be
used to maintain the platelet count above this level [43].
Timing: importance of early use
Identifying the period of time in which to treat patients with
severe sepsis is important in terms of maximizing cost-
effectiveness and decreasing morbidity and mortality. Early
identification and treatment of patients with severe sepsis
using standard supportive care significantly improves
outcomes [44]. The ENHANCE trial suggested greater
benefit in patients treated earlier (≤24 hours) rather than later
(>24 hours from first documented sepsis-induced organ
dysfunction to treatment) with DrotAA [19].
The effect of timing of DrotAA treatment on the outcome of
severe sepsis was also recently evaluated in patients
receiving either DrotAA or placebo who were enrolled in five
severe sepsis trials with similar entry criteria, using the
INDEPTH database [45]. The study demonstrated that,
compared with placebo, DrotAA treatment conferred a
potential survival benefit, regardless of time to treatment (for
instance, even when given late). However, the greatest
reduction in mortality was observed in patients who were
treated within 24 hours of developing the first organ failure
[45], with no differences found in the source of infection
according to timing of intervention [46].
The majority of the risk-adjusted survival benefit observed in
patients receiving early DrotAA treatment was accounted for
by a reduction in the number of deaths due to sepsis-induced
multiple organ failure [45]. These data were again confirmed
by a retrospective analysis conducted among 274 patients
with severe sepsis who received DrotAA in five teaching
hospitals [47]. Hospital survival was higher for patients with
prompt initiation of DrotAA (same day 67.2%, next day
59.6%, later 48.4%), with an adjusted OR (95% CI) after
controlling for age, vasopressors, mechanical ventilation, and
other organ dysfunctions of 0.52 (0.45 to 0.60). Among
those patients who received DrotAA within 24 hours,
mortality rates were similar to those in DrotAA patients
included in PROWESS. More recent data from a Canadian
multicentre observational study [48] indicate a substantial
mortality reduction (OR 0.51, 95% CI 0.28 to 0.92;
P = 0.024) in those patients who received DrotAA within
12 hours of diagnosis of severe sepsis. Multivariate analysis
in this study identified time to treatment as an important
independent but modifiable risk for death in this population.
It is acceptable, however, to make a distinction between
conditions that require early treatment with DrotAA and
others in which it is reasonable to allow some time to assess
response to standard treatments. A group of diseases that
have been shown to benefit from early treatment (within 3 to
6 hours) with DrotAA include purpura fulminans, toxic shock
syndrome, meningitis with multiple organ failure, and severe
CAP (for instance, Streptococcus pneumoniae infection). In
various other conditions, infection source control and
response to organ support may lead to clinical improvement
within 6 to 12 hours. These situations include ascending
cholangitis or pyelonephritis, secondary to obstruction,
catheter-related sepsis, and intra-abdominal collections, or
abscesses drained surgically or percutaneously [13]. If there
is deterioration or lack of response to source control, DrotAA
should be initiated in the absence of contraindications.
Managing the infusion
Learning curve
An important issue that deserves careful attention when
considering the efficacy of DrotAA in clinical trials is the
influence of the learning curve and the level of familiarity with
the treatment protocol [49]. These factors strongly influence
the survival benefit with DrotAA, as reflected by the
observation that there was either no treatment effect or even
higher mortality in patients treated with DrotAA in the
presence of one or more protocol violations pertaining, for
instance, to the timing of drug administration, the enrolment
of patients receiving an excluded medication, and/or failure to
administer study medication according to the protocol.
These violations appear to occur during the learning curve
and are less common for subsequent patients, particularly in
centres treating a large number of patients [49]. This
suggests that experience in implementing the protocol may
contribute to the greater observed treatment effect at high-
enrolling sites. A similar effect might occur in routine clinical
practice when physicians become more familiar with the
indications for and optimal timing of drug administration,
which was confirmed by data from the Polish registry [22]
Available online http://ccforum.com/content/11/S5/S7
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reasons, the SSC guidelines strongly encourage the use of a
standardized policy in the ICU for the administration of
DrotAA [4].
Interaction with other therapies
Heparin
Results of the XPRESS study [18,51] indicate that conco-
mitant prophylactic heparin does not cause a loss of efficacy
and has an acceptable safety profile in severe sepsis patients
receiving DrotAA treatment. There was a 2.7% increase in
the risk for nonserious bleeding, but similar risk for any
serious bleeding event. Co-administration of prophylactic
heparin and DrotAA was also associated with a reduction in
the incidence of ischaemic stroke. The greatest benefit was
observed in patients who were treated with heparin at
baseline and continued to receive heparin during infusion of
DrotAA. In fact, those who were receiving heparin at baseline
but were then randomized to receive placebo had a higher
mortality and a greater incidence of serious adverse events,
such as venous thrombotic events. These data suggest that
in patients who are receiving or are about to receive DrotAA,
prophylactic heparin should not be abruptly discontinued
unless the potential risks associated with heparin outweigh
the potential benefits. These data also support the contention
that clinical practice decisions to treat with DrotAA and with
prophylactic heparin can be made independently.
Continuous renal replacement therapy
Patients with end-stage renal failure requiring chronic renal
replacement therapy were excluded from the PROWESS
study. However, patients who subsequently developed acute
renal failure and required continuous renal replacement
therapy (CRRT) remained in the study as long as the heparin
dose was below 15,000 U/day. Two main issues exist
concerning concomitant use of DrotAA and renal replace-
ment therapy: the safety of DrotAA in renal failure and the
need for additional anticoagulation (systemic or regional) to
preserve circuit survival time.
No increase in the incidence of bleeding events is seen in
patients undergoing renal replacement therapy. Pharmaco-
kinetic data demonstrate that DrotAA is not eliminated by
haemofiltration or dialysis, and its serum concentration and
drug half-life are similar in patients with or without renal
failure. Therefore, no dose adjustment is required [52]. Based
on these data, patients with end-stage renal failure and
receiving chronic dialysis treatment should not be excluded
from receiving DrotAA.
It is clear that the advantage of anticoagulation on the circuit
survival time and the reduction in thrombocytopenia
secondary to platelet consumption by the clotted filter must
be balanced against the increased risk for bleeding,
particularly in the presence of clotting abnormalities induced
by sepsis. There are several possible options on how to run
CRRT during the infusion of DrotAA, using one of the
following: low-dose heparin, regional anticoagulation with
citrate or heparin/protamine, or no additional anticoagulation.
The safest option may be that of not using any additional
anticoagulation during the infusion of DrotAA. DrotAA
appears to be as effective as heparin in terms of circuit
survival time, and often the presence of thrombocytopenia or
sepsis-induced coagulopathy contraindicates the conco-
mitant use of systemic heparin [53]. Several small studies
have also confirmed that in patients at high risk for bleeding
and with some degree of coagulopathy, CRRT in the absence
of anticoagulation does not result in a shorter circuit survival
time [54,55]. Anticoagulation can be recommenced, as per
standard practice, when the infusion of DrotAA has been
completed [52].
If filter survival time without additional anticoagulation is too
short (<24 hours, in the absence of coagulopathy), then
regional anticoagulation with citrate or heparin/protamine can
be considered. Prefilter citrate anticoagulation appears to be
superior to heparin [56] and has the advantage of avoiding
systemic anticoagulation and the risk for heparin-induced
thrombocytopenia. However, it requires a strictly protocolized
practice, special dialysate/replacement fluids, and careful
monitoring of acid-base balance, electrolytes and ionized
calcium. In all cases, it is recommended that treatment with
prophylactic heparin be continued, if the patient was already
receiving it before CRRT [18,51,57].
Aspirin and warfarin
An increasing number of patients receive antiplatelet drugs or
warfarin for treatment or prevention of cardiovascular events.
The PROWESS study excluded patients on warfarin (if used
within 7 days before study entry and if the prothrombin time
exceeded the upper limit of the normal range for the
institution) and those receiving acetylsalicylic acid at a dose
of more than 650 mg/day within 3 days before the study.
However, these drugs should not represent absolute contra-
indications to the use of DrotAA but are warnings, and
coagulation abnormalities can be corrected before starting
DrotAA.
Monitoring clotting during drotrecogin alfa (activated) infusion
Both prothrombin time and activated partial thromboplastin
time can be prolonged in sepsis, whereas DrotAA has a
minimal effect on prothrombin time but can prolong the
activated partial thromboplastin time. Therefore, a prolonged
activated partial thromboplastin time cannot differentiate a
coagulopathy caused by DrotAA from that due to sepsis. If
coagulopathy worsens during the infusion of DrotAA,
exposing the patient to a substantial risk for bleeding, then
the benefits of continuing the infusion must be balanced
against the possibility of bleeding events. This does not
necessarily mandate stopping the infusion; DrotAA can be
continued provided that correction of the coagulopathy is
attempted with therapies such as fresh frozen plasma.
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DrotAA is cost-effective in the treatment of severe sepsis with
multiple organ failure when it is added to best standard care
[58,59]. An analysis of a UK group of patients with severe
sepsis and multiple organ dysfunction estimated an additional
mean cost per patient treated of £6,661, with a base-case
cost per quality-adjusted life year (QALY) of £8,228 in
patients with severe sepsis and multiple organ failure (based
on 28-day survival data) [58]. Simulation results indicate
DrotAA is a cost-effective use of resources in 98.7% of
cases. In the UK the cost for patients with severe sepsis and
multiple organ dysfunction is £6,637 pounds per QALY
based on 28-day effectiveness data and £10,937 per QALY
based on longer term follow-up data [58,59]. This cost
compares favourably with the cost per QALY of other drugs
(for instance infliximab [£23,936] and etanercept [£16,330])
or 6 months of ribavirin and interferon (£7,000).
Conservatively, in the UK for example, DrotAA could
potentially save 500 lives annually for a cost of approximately
£25 million (the UK cost for interferon-β in multiple sclerosis
is approximately £50 million). Based on the NNT to save a
life, DrotAA compares very favourably with other agents [7],
and although the cost for the initial 4 days of treatment is
high, DrotAA is less expensive if evaluated on the basis of
cost per life saved.
Conclusion
All patients in the ICU with septic shock and multiple organ
failure, in the absence of clear contraindications, should be
considered early for treatment with DrotAA. Although DrotAA
is the only drug proven effective for the treatment of this
condition, some physicians still have equipoise as to its
efficacy. Hopefully, the PROWESS Shock trial, which is due
to enrol patients worldwide early in 2008, will give clear
results and will better define the population who will benefit
most from this exciting therapy.
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